Ligand id: 3438

Name: ciprofibrate

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ciprofibrate

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 46.53
Molecular weight 288.03
XLogP 3.59
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Ciprofibrate is used to treat dyslipidemia, as an adjunct to diet and exercise in patients who either have severe hypertriglyceridaemia (with or without low HDL cholesterol) or who have mixed hyperlipidaemia and for whom a statin is contraindicated or not tolerated. This drug is not approved by the US FDA or the EMA, but has approval from many national regulatory agencies (see's international drugs page for ciprofibrate).
Mechanism Of Action and Pharmacodynamic Effects
Fibrate drugs accelerate PPAR-induced break down of dietary fat, especially triglycerides and cholesterol., thus helping to clear the blood of cholesterol and triglycerides.
External links